All In Biotech

Drug Trial Radar · NCT00892281

ORCA - Oracea® for Rosacea: A Community-based Assessment

A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [Doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea

Last checked: Nov 19, 2026Latest source record: Aug 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,421

Actual

Start

Apr 2009

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
May 4, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.

Conditions

  • Rosacea

Interventions

  • doxycycline (Oracea®) 40 mg modified release as monotherapyDrug

    Take once daily in the morning

  • doxycycline (Oracea®) 40 mg modified release as add-on therapyDrug

    Take once daily in the morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Investigator's Global Assessment (IGA) Score From Baseline to EndpointTime frame: Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • REGISTRAT® - MAP1, Inc. (CRO)

    Lexington, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.